PMID- 33071677
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20220417
IS  - 1540-8183 (Electronic)
IS  - 0896-4327 (Print)
IS  - 0896-4327 (Linking)
VI  - 2020
DP  - 2020
TI  - Bivalirudin vs. Heparin on Radial Artery Thrombosis during Transradial Coronary 
      Intervention: An Optical Coherence Tomography Study.
PG  - 7905021
LID - 10.1155/2020/7905021 [doi]
LID - 7905021
AB  - OBJECTIVES: This study aimed to evaluate the antithrombotic efficacy between 
      bivalirudin and unfractionated heparin (UFH) on radial artery thrombosis (RAT) 
      during transradial coronary intervention (TRI) by optical coherence tomography 
      (OCT). METHODS AND RESULTS: We consecutively reviewed a total of 307 patients who 
      underwent radial artery OCT inspection after TRI in our centre from October 2017 
      to January 2019; afterwards, 211 screened patients were divided into the UFH 
      group (n = 144) and the bivalirudin group (n = 67) according to their 
      anticoagulation strategy during TRI. The thrombosis in the radial artery was 
      observed in 51 cases (24.17%) with a median thrombus volume of 0.054 mm(3) 
      (0.024, 0.334) and median thrombus score of 7 (4, 15). Thrombus occurred in 28 
      cases in the bivalirudin group with an incidence of 41.8%, which was 
      significantly higher than that in the UFH group (n = 23, 16.0%, P < 0.001). This 
      difference was even more remarkable after propensity score matching (bivalirudin 
      group n = 22, 42.3% vs. UHF group n = 11, 13.9%, P < 0.001). Multivariate 
      logistic analysis revealed that bivalirudin increased the RAT risk by 3.872 times 
      (95% CI 2.006-8.354, P < 0.001) after adjustment for the other predictors. 
      CONCLUSION: In this present study, the use of bivalirudin was associated with a 
      higher risk of RAT than UFH. It highlighted UFH should be a more considerable 
      choice to prevent radial artery access thrombosis in TRI.
CI  - Copyright (c) 2020 Zijing Liu et al.
FAU - Liu, Zijing
AU  - Liu Z
AD  - Department of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing 
      10000, China.
FAU - Wang, Guozhong
AU  - Wang G
AD  - Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, 
      Beijing 100000, China.
FAU - Niu, Dan
AU  - Niu D
AD  - Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, 
      Beijing 100000, China.
FAU - Wu, Yongxia
AU  - Wu Y
AD  - Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, 
      Beijing 100000, China.
FAU - Li, Zixuan
AU  - Li Z
AD  - Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, 
      Beijing 100000, China.
FAU - Zhang, Libin
AU  - Zhang L
AD  - Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, 
      Beijing 100000, China.
FAU - Zhu, Guohua
AU  - Zhu G
AD  - Department of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing 
      10000, China.
FAU - Hua, Qi
AU  - Hua Q
AUID- ORCID: 0000-0002-5115-2149
AD  - Department of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing 
      10000, China.
FAU - Guo, Jincheng
AU  - Guo J
AUID- ORCID: 0000-0001-6173-6386
AD  - Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, 
      Beijing 100000, China.
LA  - eng
PT  - Journal Article
DEP - 20200926
PL  - United States
TA  - J Interv Cardiol
JT  - Journal of interventional cardiology
JID - 8907826
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Catheterization, Peripheral/*adverse effects/methods
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/adverse effects
MH  - *Heparin/administration & dosage/adverse effects
MH  - *Hirudins/administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Peptide Fragments/administration & dosage/adverse effects
MH  - *Percutaneous Coronary Intervention/adverse effects/methods
MH  - *Radial Artery/diagnostic imaging/pathology/surgery
MH  - Recombinant Proteins/administration & dosage/adverse effects
MH  - Risk Adjustment/methods
MH  - *Thrombosis/etiology/prevention & control
MH  - Tomography, Optical Coherence/methods
MH  - Treatment Outcome
PMC - PMC7533783
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/10/20 06:00
MHDA- 2021/03/09 06:00
PMCR- 2020/09/26
CRDT- 2020/10/19 05:54
PHST- 2020/06/07 00:00 [received]
PHST- 2020/08/03 00:00 [revised]
PHST- 2020/09/12 00:00 [accepted]
PHST- 2020/10/19 05:54 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
PHST- 2020/09/26 00:00 [pmc-release]
AID - 10.1155/2020/7905021 [doi]
PST - epublish
SO  - J Interv Cardiol. 2020 Sep 26;2020:7905021. doi: 10.1155/2020/7905021. 
      eCollection 2020.